Abstract
I read with interest the manuscript by Cattaneo.[1] Within the context of the discussion on platelet ADP receptors, the author states, “P2Y12 is the target of efficacious antithrombotic agents like ticlopidine and clopidogrel, which are already used in clinical practice, and the AIDS-related complex compounds, one of which is currently under evaluation…” (emphasis added). The author sites the work by Humphries[2] in support.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
